Clinical Trials

There
are 2 clinical trials
for endometrioid adenocarcinoma, of which 1
is
open and 1
is
completed or closed. 
Of the
trials that contain
endometrioid adenocarcinoma as an inclusion criterion, 1 is phase 2 (1 open) and 1 is no phase specified (0 open). 

Ipilimumab, nivolumab, and ponatinib
are the most common
interventions in
endometrioid adenocarcinoma clinical trials. 

Drugs Being Investigated in Endometrioid Adenocarcinoma Trials by Recruiting Status

Significant Genes in Endometrioid Adenocarcinoma

FGFR2
+

FGFR2 is altered in 10.81% of endometrioid adenocarcinoma patients [2]. 

FGFR2 is an inclusion eligibility criterion in 1 clinical
trial
for endometrioid adenocarcinoma, of which 0
are open and 1
is closed. 
Of the
trial that contains
FGFR2 status and endometrioid adenocarcinoma as inclusion criteria, 1 is no phase specified (0 open) [3]. 

MLH1 is an inclusion eligibility criterion in 1 clinical
trial
for endometrioid adenocarcinoma, of which 1
is open and 0
are closed. 
Of the
trial that contains
MLH1 status and endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3]. 

MSH2 is an inclusion eligibility criterion in 1 clinical
trial
for endometrioid adenocarcinoma, of which 1
is open and 0
are closed. 
Of the
trial that contains
MSH2 status and endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3]. 

MSH6 is an inclusion eligibility criterion in 1 clinical
trial
for endometrioid adenocarcinoma, of which 1
is open and 0
are closed. 
Of the
trial that contains
MSH6 status and endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3]. 

PMS2 is an inclusion eligibility criterion in 1 clinical
trial
for endometrioid adenocarcinoma, of which 1
is open and 0
are closed. 
Of the
trial that contains
PMS2 status and endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3]. 

References

2.  The AACR Project GENIE Consortium.  AACR Project GENIE: powering precision medicine through an international consortium.  Cancer Discovery.  2017;7(8):818-831.  Dataset Version 6.  This dataset does not represent the totality of the genetic landscape; see paper for more information. 

3.  All assertions and clinical trial landscape data are curated from primary sources.  You can read more about the curation process here.